Autolus Therapeutics plc

AUTL

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001730463

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $589.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress, fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Mar 27, 2026 231 days before the rescan; latest periodic filing 10-Q received Nov 10, 2026
Last close	$1.20 2026-11-12; market equity $318.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells. We believe our programmed T cell therapies have the potential to be best-in-class and offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 89.3						
Gross profitability	(3.6%)	32.3%		98.9	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(0.6%)	(6.6%)		79.7	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 2						
Solvency, sleeve percentile 47.0						
Twelve-month failure probability	not computable	0.08%				
liabilities and a nearby cover-page share count are required at 2025-12-31						
Altman Z double-prime	(6.27)	(0.35)		55.5	744	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	(7.38x)	(4.51x)		54.5	78	2025-12-31
Current ratio	5.94x	2.95x		30.9	826	2025-12-31
Growth and financing, sleeve percentile 12.9						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 2						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	not computable	2.2%				
four consecutive annual observations are required						
Net share issuance, one year	0.01%	2.5%		12.9	627	2026-03-26

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	25.2%	(1.9%)	66
Distance from 52-week high	(53.1%)	(30.8%)	28
EBIT to enterprise value	not computable	(1.9%)	
Free cash flow yield	(95.5%)	(1.0%)	8
Book value to price	0.09	0.28	23
Sales to price	0.24	0.29	43
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.06	(0.19)	66

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	pass

Cash, filings, liquidity

Cash and equivalents	$245.4M
Operating cash flow, four quarters	-$176.2M
Months of runway	16.7
Days since last periodic filing	3 (10-Q received Nov 10, 2026)
Median daily dollar volume, 63 sessions	$3.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$75.4M	2025-12-31	2026-03-27	10-K	26-000038
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$96.4M	2025-12-31	2026-03-27	10-K	26-000038
3	assets	us-gaap:Assets	$589.1M	2025-12-31	2026-03-27	10-K	26-000038
4	net income	us-gaap:NetIncomeLoss	-$287.5M	2025-12-31	2026-03-27	10-K	26-000038
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$283.6M	2025-12-31	2026-03-27	10-K	26-000038
6	assets	us-gaap:Assets	$782.7M	2024-12-31	2026-03-27	10-K	26-000038
7	current assets	us-gaap:AssetsCurrent	$435.9M	2025-12-31	2026-03-27	10-K	26-000038
8	current liabilities	us-gaap:LiabilitiesCurrent	$73.4M	2025-12-31	2026-03-27	10-K	26-000038
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.4B	2025-12-31	2026-03-27	10-K	26-000038
10	operating income	us-gaap:OperatingIncomeLoss	-$270.5M	2025-12-31	2026-03-27	10-K	26-000038
11	book equity	us-gaap:StockholdersEquity	$178.1M	2025-12-31	2026-03-27	10-K	26-000038
12	liabilities	us-gaap:Liabilities	$410.9M	2025-12-31	2026-03-27	10-K	26-000038
13	interest expense	us-gaap:InterestExpense	$36.7M	2025-12-31	2026-03-27	10-K	26-000038
14	revenue	us-gaap:Revenues	$10.1M	2024-12-31	2025-03-20	10-K	25-000019
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$19.0M	2025-12-31	2026-03-27	10-K	26-000038
16	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$8.3M	2025-12-31	2026-03-27	10-K	26-000038
17	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$285.6M	2025-12-31	2026-03-27	10-K	26-000038
18	income tax	us-gaap:IncomeTaxExpenseBenefit	$2.0M	2025-12-31	2026-03-27	10-K	26-000038
19	current assets	us-gaap:AssetsCurrent	$660.9M	2024-12-31	2026-03-27	10-K	26-000038
20	current liabilities	us-gaap:LiabilitiesCurrent	$60.7M	2024-12-31	2026-03-27	10-K	26-000038
21	assets	us-gaap:Assets	$375.4M	2023-12-31	2025-03-20	10-K	25-000019
22	assets	us-gaap:Assets	$406.1M	2023-09-30	2024-03-21	10-K	24-000048
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	266,143,286	2026-03-26	2026-03-27	10-K	26-000038
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	266,128,900	2025-03-19	2025-03-20	10-K	25-000019

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.